# A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

> **NCT06641388** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 180 (estimated)

## Conditions studied

- Healthy Subjects (HS)

## Interventions

- **DRUG:** Ebronucimab
- **DRUG:** Ebronucimab

## Key facts

- **NCT ID:** NCT06641388
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-06-17
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06641388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06641388, "A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06641388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*